• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
ACW
Click for more information
0.00% 2.4¢

ACTINOGEN MEDICAL LIMITED - Charts / Financials

Market Cap $65.08M  ! watchlist Created with Sketch. Add to my watchlist
Healthcare Biotechnology

Actinogen Medical (ACW) is an ASX-listed, biotechnology company developing a novel... Actinogen Medical (ACW) is an ASX-listed, biotechnology company developing a novel therapy for neurological diseases associated with dysregulated brain cortisol. There is a strong association between cortisol and detrimental changes in the brain, affecting cognitive function, harm to brain cells and long term cognitive health.More

Corporate Spotlight

Actinogen is a neurotherapeutics developer realizing a revolutionary therapy so neurology patients and their families can live their best lives.
View the full Corporate Spotlight arrow Created with Sketch.

Actinogen reveals XanaCIDD phase 2a trials
refresh Created with Sketch. REFRESH
Last update - 15.59pm 23/08/2024 (20 minute delay) ?
Day
Open 2.4¢   Day High 2.5¢   Day Low 2.1¢
Daily Volume 22844156
Bids   Sellers
Number Price Volume   Number Price Volume
5 2.3¢ 431842   1 2.4¢ 499979

Directors & Senior Management

Dr. Steven Gourlay Chief Executive Officer, Managing Director
Mr. William Souter Chief Financial Officer
Ms. Tamara Miller Senior Vice President - Product Development
Ms. Cheryl Townsend Vice President of Clinical Operations
Dr. Dana C. Hilt Chief Medical Officer
Prof. Paul Rolan Head - Clinical Pharmacology, Lead Physician - Depression
Ms. Therese Russell Head of People & Infrastructure
Dr. Christian Toouli Head of Business Development
Mr. Peter Gordon Webse Company Secretary
Dr. Geoffrey E. D. Brooke Non-Executive Chairman of the Board
Mr. Malcolm John Mccomas Non-Executive Director
Mr. George Morstyn Non-Executive Director
Dr. Nicki J. Vasquez Non-Executive Independent Director

Data source: Refinitiv

(20min delay)
Last
2.4¢ 		Change
0.000(0.00%) 		Mkt cap ! $65.08M
Open High Low Value Volume
2.4¢ 2.5¢ 2.1¢ $526.7K 22.84M

Buyers (Bids)

No. Vol. Price($)
5 431842 2.3¢
 

Sellers (Offers)

Price($) Vol. No.
2.4¢ 499979 1
View Market Depth
Last trade - 16.10pm 23/08/2024 (20 minute delay) ?
Last
2.4¢ 		  Change
0.000 ( 1.69 %)
Open High Low Volume
2.4¢ 2.5¢ 2.1¢ 9368279
Last updated 15.59pm 23/08/2024 ?

Top Stories

Reporting wrap: Inghams, Accent, Mayne Pharma

Inghams Group Ltd, Accent Group Ltd and Mayne Pharma Group Ltd all reported final year results for the 2024 fiscal year.
Chariot locks in high-potential drill target at Black Mountain, one of the USA's largest lithium landholdings A southward cluster of outcropping pegmatites on-site Chariot Corporation's (ASX:CC9) flagship Black Mountain hard rock lithium project has led management and geotechs to sign off on a promising future drilling target for the company as exploration on-site gathers pace.
IPH raises $100M to buy up Canadian IP firm Bereskin & Parr IPH Ltd has raised $100 million in an institutional placement to support the acquisition, while also launching a share purchase plan.
Raiden gears up for exploration in final quarter of 2024 Raiden Resources Ltd - which is exploration for a multiplicity of minerals in the Pilbara region of WA - is looking ahead to a busy schedule.
Noronex kicks off EM survey at Humpback, Namibia – part of South32's earn-in deal to access Kalahari Copper Belt Noronex Limited (ASX:NRX) has kicked off a gravity EM survey at the Damara project in Namibia – part of its earn-in deal with South32.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.